CollPlant Biotechnologies Ltd CLGN
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.94
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $515.0K | $11.0M | $299.0K | $15.6M | $6.1M | $2.3M | $5.0M | $463.0K | — |
| Cost of revenue | $835.0K | $1.6M | $2.0M | $400.0K | $2.0M | $3.0M | $1.9M | $1.7M | — | — |
| Gross profit | $1.5M | -$1.1M | $9.0M | -$101.0K | $13.6M | $3.1M | $439.0K | $3.4M | — | — |
| R&D | $8.2M | $10.5M | $10.5M | $10.3M | $7.6M | $4.1M | $4.4M | $3.9M | $584.0K | — |
| SG&A | $4.8M | $5.6M | $6.0M | $6.7M | $5.9M | $4.7M | $3.7M | $3.7M | — | — |
| Total operating expenses | — | — | — | — | — | $34.0K | $3.3M | $2.2M | — | — |
| Operating income | -$11.5M | -$17.3M | -$7.5M | -$17.1M | $65.0K | -$5.6M | -$7.6M | -$4.2M | -$6.0M | — |
| Pre-tax income | — | $29.4M | $53.0M | — | — | — | — | — | — | — |
| Income tax | — | $46.0M | $60.0M | — | — | — | — | — | — | — |
| Net income | -$11.5M | -$16.6M | -$7.0M | -$16.9M | $237.0K | -$5.8M | -$11.2M | -$6.2M | -$6.1M | — |
| EPS, basic | -0.94 | -1.45 | -0.62 | -1.53 | 0.02 | -0.84 | -2.23 | — | — | — |
| EPS, diluted | -0.94 | -1.45 | -0.62 | -1.53 | 0.02 | -0.84 | -2.23 | 1.43 | — | — |
| Shares, diluted (wtd. avg.) | 12.2M | 11.5M | 11.4M | 11.0M | 12.0M | 6.9M | 5.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.6M | $11.9M | $26.7M | $29.9M | $13.4M | $3.5M | $3.8M | $5.7M | $5.3M | — |
| Receivables | $1.0K | $150.0K | — | $9.0K | $270.0K | $830.0K | $79.0K | — | — | — |
| Inventory | $573.0K | $440.0K | $714.0K | $1.4M | $1.1M | $1.3M | $888.0K | — | — | — |
| Total current assets | $6.7M | $13.2M | $28.0M | $31.7M | $45.1M | $5.7M | $5.0M | — | — | — |
| Property, plant and equipment | $1.5M | $2.3M | $2.8M | $3.0M | $2.7M | $2.1M | $2.3M | — | — | — |
| Other intangibles | $73.0K | $131.0K | $188.0K | $245.0K | $243.0K | $82.0K | — | — | — | — |
| Total assets | $10.8M | $18.7M | $34.1M | $37.8M | $51.2M | $10.8M | $10.8M | $8.8M | $8.1M | — |
| Short-term debt | — | — | — | $321.0K | $219.0K | — | — | — | — | — |
| Total current liabilities | $2.7M | $3.0M | $3.3M | $3.1M | $3.0M | $3.4M | $3.5M | — | — | — |
| Long-term debt | — | — | — | — | $30.0K | $11.0K | $63.0K | — | $2.0M | — |
| Total liabilities | $4.7M | $5.2M | $5.8M | $5.5M | $6.1M | $6.4M | $6.7M | — | — | — |
| Retained earnings | -$124.8M | -$113.3M | -$96.7M | -$89.7M | -$72.8M | -$73.0M | -$67.3M | — | — | — |
| Total equity | $6.1M | $13.5M | $28.3M | $32.3M | $45.1M | $4.5M | $4.1M | $5.4M | $5.2M | $1.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.4M | -$14.1M | -$2.8M | -$13.7M | $2.5M | -$4.5M | -$5.7M | -$1.2M | — | — |
| Depreciation and amortisation | $912.0K | $1.0M | $1.1M | $1.1M | $773.0K | $660.0K | $539.0K | $342.0K | — | — |
| Stock-based compensation | $999.0K | $1.7M | $1.9M | $2.2M | $1.6M | — | — | — | — | — |
| Capital expenditure | $28.0K | $483.0K | $954.0K | $1.3M | $1.4M | $437.0K | $1.5M | $832.0K | — | — |
| Investing cash flow | -$27.0K | -$539.0K | -$1.2M | $28.9M | -$31.6M | -$519.0K | -$1.5M | -$832.0K | — | — |
| Financing cash flow | $3.1M | $9.0K | $1.1M | $1.9M | $38.8M | $4.5M | $5.4M | $2.8M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-034393.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $463.0K | $5.0M | $2.3M | $6.1M | $15.6M | $299.0K | $11.0M | $515.0K | $2.4M |
| Gross profit | — | — | $3.4M | $439.0K | $3.1M | $13.6M | -$101.0K | $9.0M | -$1.1M | $1.5M |
| Net income | — | -$6.1M | -$6.2M | -$11.2M | -$5.8M | $237.0K | -$16.9M | -$7.0M | -$16.6M | -$11.5M |
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $159.78B | 57.5x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.34B | 48.7x | 11.5% |
| STE | STERIS plc | $22.63B | 29.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.80B | 27.8x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $10.98B | 27.3x | 0.9% |
| MSA | MSA Safety Inc | $7.03B | 25.7x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.90B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.28B | 29.4x | 7.5% |